A GLP-1 receptor agonist, FDA-approved under brand names for diabetes and weight management, and the most widely used peptide of the GLP-1 class.
Reviewed for accuracy · Last reviewed July 7, 2026Semaglutide acts on the GLP-1 receptor, which slows gastric emptying, reduces appetite, and improves blood-sugar regulation. It's approved under brand names for both type 2 diabetes and weight management, and it's the most widely used of the GLP-1 peptides. It's given as a once-weekly subcutaneous injection, usually starting low and stepping up every four weeks.
Like tirzepatide, people sourcing it independently as a vial rather than a prefilled pen often need to work out unit conversions by hand. The titration schedule and the units chart below are a starting point. Recalculate for your own vial with the calculator.
The weight-management titration (Wegovy) begins at 0.25 mg once weekly and steps up every four weeks toward a 2.4 mg maintenance dose. The diabetes product (Ozempic) tops out lower. Vial users often convert milligrams to units by hand.
Read the full Semaglutide dosage guide →Nausea and diarrhea are the most common adverse events, typically transient and mild to moderate. The label carries a boxed warning for thyroid C-cell tumors.
Read the full Semaglutide side effects guide →Keep unmixed vials refrigerated and away from light. Once reconstituted, most research reports store it refrigerated for roughly 4 weeks. See the full storage & safety guide for handling and disposal basics.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting or adjusting any compound.